Your new post is loading...
Your new post is loading...
BigField GEG Tech's insight:
The authors describe a therapeutic strategy to preserve β-cell function by overexpression of follistatin (FST) using an AAV vector (AAV8-Ins-FST) in diabetic mouse model.Overexpression of FST in the pancreas of db/db mouse increased β-cell islet mass, decreased fasting glucose level, alleviated diabetic symptoms, and essentially doubled lifespan of the treated mice.
BigField GEG Tech's insight:
The authors used a culture model of human erythropoiesis to directly compare two insulated, self-inactivating, and erythroid-specific lentiviral vectors, encoding for γ-globin or a modified β-globin. They observed that the lentiviral transductions did not impair cell growth or differentiation and increased the levels of anti-sickling globin this which could be compatible with a therapeutic treatment.
BigField GEG Tech's insight:
In this review, the authors provided a comprehensive overview on the basic principles and potential co-factors concurring in the generation of adverse events reported in gene therapy clinical trials using integrating vectors. Additionally, they summarized the available systems to assess genotoxicity at the preclinical level and they shed light on the issues affecting the predictive value of these assays when translating the results into the clinical arena. In the last section of the review they briefly touched on the future trends and how they could increase the safety of gene therapy employing integrating vector technology to take it to the next level.
BigField GEG Tech's insight:
The authors transduced CD4+ cells with a lentiviral vector which expresses Foxp3. They observed that full length and N-cleaved Foxp3 transduced CD4+ T cells similarly suppressed the in vitro proliferation of Teffs. However, the C- or N&C-cleaved Foxp3 forms afforded almost no suppressive function, indicating a crucial role of the human Foxp3 C-terminal region in Tregs suppressive activity, in marked contrast with the report of superior suppressive activity for the C-cleaved murine Foxp3 compared to the full length.
BigField GEG Tech's insight:
Thanks to a lentiviral vector which expressed glucosidase beta acid under the control of PGK or CD68 promoter, the scientists report prevention of, as well as reversal of, manifest disease symptoms after lentiviral gene transfer.
BigField GEG Tech's insight:
The authors have constructed several lentiviral vector to express the factor VIII under the control of different promoters : MND, EF1 and glycoprotein-1bα (G1B). Their results show that only the G1B-FVIII vector achieves long-term and efficient expression, resulting in partial correction of hemophilia A. This work illustrates the importance of the choice of the promoter in lentiviral vector system. For this reason, GEG-tech offers sets of vectors ready to used which allow to select the best promoter in a given experimental context. www.geg-tech.com/Vectors/index.php/sets.html?element_tryout=10
BigField GEG Tech's insight:
In this study, the scientists generated two chimeric envelopes containing the extra-virion and transmembrane domain of rabies SADB19 or CVS-N2c with the intra-virion domain of vesicular stomatitis virus. Injection of the SADB19 chimeric viral vector into the lumbar spinal cord of adult mice mediated a strong preference for gene transfer to local neurons and axonal terminals, with retrograde transport to neurons in the brainstem, hypothalamus and cerebral cortex.
BigField GEG Tech's insight:
Thanks to a lentiviral vectors, the scientists examined the potential of NIS gene therapy as a therapeutic approach in nasopharyngeal carcinoma by performing non-invasive imaging using 125I and 131I therapy in vivo.
BigField GEG Tech's insight:
Lentiviral Vectors (LV) pseudotyped with the measles virus (MV) is a powerfull gene transfer tool with many applications. However the problem with MV pseudotyped LV vectors is the difficulty to obtain vector productions with high titer. In this study, the scientists have adapted an anion-exchange membrane chromatography method to concentrate MV glycoprotein-pseudotyped LV vectors. In this manner, up to 60% of the input vectors with an up to 5300-fold reduction in volume was achieved.
BigField GEG Tech's insight:
This review summarizes gene therapy studies performed in a canine model of XSCID to evaluate the efficacy of γ-retroviral, lentiviral and foamy viral vectors for treating XSCID and a novel method of vector delivery.
BigField GEG Tech's insight:
The authors used lentiviral vectors to overexpress some CARs containing CD28 and TCR/CD3 zeta chain tandem signaling domains which lead to constitutive activation and proliferation of primary human T cells. The CAR T cells that they have identified have a constitutive secretion of large amounts of diverse cytokines and consequently do not require the addition of exogenous cytokine or feeder cells in order to maintain proliferation. Furthermore, the scientists report that one mechanism that can result in the phenotype of CARs with continuous T-cell proliferation is the density of CARs at the cell surface.
|
BigField GEG Tech's insight:
The authors assessed the CD30-specific scFv for its ability to retarget lentiviral vectors (LVs) to CD30 and to mediate selective gene transfer into CD30-positive cells. They observed that, in some experimental contexts, gene transfer into CD30-positive cells increased ∼100-fold due to improved transport of the H-scFv protein to the plasma membrane.
BigField GEG Tech's insight:
To optimize Zinc Finger Nuclease (ZFN) delivery from a single lentiviral vector (LV), the authors used a codon swapping strategy to both drastically disrupt sequence identity between ZFN monomers and to reduce sequence repeats within a monomer sequence. In this way, they observed a ZFN activity up to 7 fold increased compared to non optimized ZFN LV. Furthermore, they reported for the first time successful ZFN-induced targeted DNA double-strand breaks in primary cells (hepatocytes) and in vivo (liver) after delivery of a single non integrating lentiviral vector encoding two ZFNs.
BigField GEG Tech's insight:
The authors show that eCD4-Ig, a fusion of CD4-Ig with a small CCR5-mimetic sulfopeptide, binds avidly and cooperatively to the HIV-1 envelope glycoprotein (Env) and is more potent than the best broadly neutralizing antibodies (bNAbs). For example, eCD4-Ig efficiently neutralized 100% of a diverse panel of neutralization-resistant HIV-1, HIV-2 and simian immunodeficiency virus isolates, including a comprehensive set of isolates resistant to the CD4-binding site bNAbs VRC01, NIH45-46 and 3BNC117.
BigField GEG Tech's insight:
In order to know the role ofPlatelet-derived growth factor-BB (PDGF-BB), the authors performed it knockdown in cultured cardiomyocytes thanks to a lentiviral vectors which expresses shRNA. They observed that the number of apoptotic cells and the level of LDH were significantly increased and that the beat rhythm was reduced.
BigField GEG Tech's insight:
Thanks to a lentiviral vector which expressesTNF-α RNAi, the authors showed that, following contusion spinal cord injury (SCI) in rats, the inhibition of TNF-α increases the expression of PDRX6 in neurons. This suggests a recovery of motor function and provides a new strategy or target for the clinical treatment of SCI in future.
BigField GEG Tech's insight:
The scientists constructed a lentiviral vector which expressed EGFP under the control of Figal promoter. Figla is specifically expressed in female mice oocyte, in this way, this vector could allow to study the development and the differentiation of germ cells derived from stem cells.
BigField GEG Tech's insight:
the authors developed an integration-deficient lentiviral vector termed ID-VP02 that is designed to deliver antigen-encoding nucleic acids selectively to human DCs in vivo. ID-VP02 utilizes a genetically and glycobiologically engineered Sindbis virus glycoprotein to target human DCs through the C-type lectin DC-SIGN (CD209) and also binds to the homologue murine receptor SIGNR1.
|
|
|
Scooped by
BigField GEG Tech
January 29, 2015 11:14 AM
|
The authors found that the targeting of some parts of the intron promoted trans-splicing more efficiently than the targeting of other areas, and that trans-splicing rate could be increased by modifying the replacement sequence. They tested AAV gene transfer in a mouse model of retinitis pigmentosa that expresses a mutant allele of the human rhodopsin gene, and demonstrated the feasability of trans-splicing in vivo.
|
|
Scooped by
BigField GEG Tech
January 28, 2015 2:40 AM
|
In this study, the authors co-delivered piggyBac/Ad or piggyBac/AAV with Ad-transposase to cells in vitro and mouse airways in vivo and demonstrated efficient transduction, transposase-mediated integration, and persistent expression. Interestingly previous reports using the Sleeping Beauty based DNA transposon and Ad vectors observed that the Ad genome required Flp-mediated recombination that resulted in circularization before releasing the Sleeping Beauty transposon. PiggyBac doesn’t require this circularization step for an unclear reason.
|
|
Scooped by
BigField GEG Tech
January 22, 2015 6:20 AM
|
The authors developed an endogenous gene knockdown/rescue strategy that combines RNAi selectivity with a highly efficient CRISPR directed recombinant Adeno-Associated Virus (rAAV) mediated gene targeting approach to introduce allele-specific mutations plus an allele-selective siRNA Sensitive (siSN) site that allows for studying gene mutations while maintaining endogenous expression and regulation of the gene of interest.
|
|
Scooped by
BigField GEG Tech
January 16, 2015 1:28 AM
|
In this paper, the scientists studied the effect of ET-1 RNAi and Endostar in PC-3 prostatic cancer cells. A lentiviral vector was used in the establishment of ET-1 knockdown PC-3 cells. They shown that ET-1 mRNA and protein in ET-1 knockdown PC-3 cells were reduced to 26.4% and 22.4%, respectively. ET-1 RNAi and Endostar both were effective for the suppression of progression and invasion of PC-3 cells.
Your new post is loading...
In this study, the scientists established a methodology allowing an adjustment of expression windows to a period of choice, even for the simultaneous expression of multiple transgenes, based on the repeated administration of lentiviral and gammaretroviral vectors.
www.geg-tech.com